The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases. A new City of Hope chimeric antigen receptor CAR T cell trial - the first to focus on HER2-postive breast cancer patients with brain metastases - is now enrolling potential participants. The phase 1 trial will be conducted in an outpatient setting and will also be the first to use intraventricular delivery of CAR T cells directly to the brains of these patients. It will test the safety and effectiveness of the CAR T cell therapy for patients who have tried other types of treatment that are no longer effective.
CITY OF HOPE
City of Hope Jobs
Breast cancer patients, for example, typically do not die because cancer returns in their breast, they die because it spreads to other parts of their body. The most dangerous of which is the brain. Approximately 40 percent of all women with HER2-positive breast cancer will develop brain metastases. Now City of Hope researchers have found how this happens.
City of Hope Breast Fellowship
It came as a devastating blow to Kennedy, who was 52 at the time, and considered himself to be in the best shape of his life. Kennedy was diagnosed with multiple myeloma, a cancer of the plasma cells that are found in the bone marrow and are an important part of the immune system. When his chemotherapy and infusion treatments began at the City of Hope in Duarte, he had to drive more than miles each day to get them. On Monday, Feb.
Main: New Patient Services: Founded in , City of Hope began focusing on cancer research and treatment in the late s. Receiving its NCI designation in and its designation as a comprehensive cancer center in , City of Hope is today a biomedical research, treatment, and education center. In this multidisciplinary, interactive environment, basic, clinical, translational, and prevention and control scientists work closely together. Their work is a continuum, starting with research on the biomedical mechanisms of cancer genesis and progression, moving on to the development of new therapies, testing those treatments in clinical trials, and, finally, delivering the best in patient care and providing support and education to patients, their families, and the public.